<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10536</article-id><article-id pub-id-type="doi">10.32607/20758251-2014-6-4-116-118</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Short communications</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Краткие сообщения</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Phosphoryl Guanidines: A New Type of Nucleic Acid Analogues</article-title><trans-title-group xml:lang="ru"><trans-title>Фосфорилгуанидины. Новый класс аналогов нуклеиновых кислот</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kupryushkin</surname><given-names>M. S.</given-names></name><name xml:lang="ru"><surname>Купрюшкин</surname><given-names>М. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dast@niboch.nsc.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pyshnyi</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Пышный</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dast@niboch.nsc.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stetsenko</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Стеценко</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dast@niboch.nsc.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Институт химической биологии и фундаментальной медицины СО РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2014</year></pub-date><volume>6</volume><issue>4</issue><issue-title xml:lang="en">VOL 6, NO4 (2014)</issue-title><issue-title xml:lang="ru">ТОМ 6, №4 (2014)</issue-title><fpage>116</fpage><lpage>118</lpage><history><date date-type="received" iso-8601-date="2020-01-17"><day>17</day><month>01</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Kupryushkin M.S., Pyshnyi D.V., Stetsenko D.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Купрюшкин М.С., Пышный Д.В., Стеценко Д.А.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Kupryushkin M.S., Pyshnyi D.V., Stetsenko D.A.</copyright-holder><copyright-holder xml:lang="ru">Купрюшкин М.С., Пышный Д.В., Стеценко Д.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/10536">https://actanaturae.ru/2075-8251/article/view/10536</self-uri><abstract xml:lang="en"><p>A new type of nucleic acid analogues with a phosphoryl guanidine group is described. Oxidation of polymer-supported dinucleoside 2-cyanoethyl phosphite by iodine in the presence of 1,1,3,3-tetramethyl guanidine yields a dinucleotide with an internucleoside tetramethyl phosphoryl guanidine (Tmg) group as the main product. The Tmg group is stable under conditions of solid-phase DNA synthesis and subsequent cleavage and deprotection with ammonia. Oligonucleotides with one or more Tmg groups bind their complementary DNA or RNA with affinity similar to that of natural oligodeoxyribonucleotides.</p></abstract><trans-abstract xml:lang="ru"><p>Описан новый класс аналогов нуклеиновых кислот, содержащих фосфорилгуанидиновую группу. Окисление связанного с полимерным носителем динуклеозид-β-цианэтилфосфита йодом в присутствии 1,1,3,3-тетраметилгуанидина приводит к образованию динуклеотида, содержащего незаряженную тетраметилфосфорилгуанидиновую группу (Tmg), в качестве основного продукта. Tmg-группа устойчива в условиях твердофазного олигонуклеотидного синтеза, последующего удаления защитных групп и отщепления олигонуклеотида от полимерного носителя аммонолизом. Олигонуклеотиды, содержащие Tmg-группу, способны связываться с комплементарными последовательностями ДНК и РНК со сродством, лишь незначительно отличающимся от сродства природных олигодезоксирибонуклеотидов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>nucleic acid analogue</kwd><kwd>modified oligonucleotide</kwd><kwd>solid-phase synthesis</kwd><kwd>tetramethylguanidine</kwd><kwd>phosphoryl guanidine</kwd><kwd>phosphite</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аналоги нуклеиновых кислот</kwd><kwd>модифицированный олигонуклеотид</kwd><kwd>твердофазный синтез</kwd><kwd>тетраметилгуанидин</kwd><kwd>фосфорилгуанидин</kwd><kwd>фосфит</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This work was partly carried out with support of the Government of the Russian Federation for research projects implemented under supervision of world leading scientists (agreement No. 14.B25.31.0028 with S. Altman as a leading scientist) and the Russian Foundation for Basic Research (grant № 13-04-01176).</funding-statement><funding-statement xml:lang="ru">Работа выполнена при частичной финансовой поддержке Правительства Российской Федерации для научных проектов, выполненных под руководством ведущих мировых ученых (соглашение № 14.В25.31.0028 с С. Альтманом как ведущим ученым), и гранта РФФИ № 13-04-01176.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>[1] Goodchild J. N.Y. // Therapeutic Oligonucleotides: Methods and Protocols. Methods Mol. Biol. / Humana Press, 2011 2011, V.764, P.340</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>[2] Bell N.M., Micklefield J. // ChemBioChem. 2009, V.10, №17, P.2691-2703</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>[3] Egholm M., Buchardt O., Nielsen P.E., Berg R.H. // J. Am. Chem. Soc. 1992, V.114, №5, P.1895-1897</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>[4] Summerton J., Weller D. // Antisense Nucleic Acid Drug Dev. 1997, V.7, №3, P.187-195</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>[5] Nielsen P.E. // Mol. Biotechnol. 2004, V.26, №3, P.233-248</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>[6] Karkare S., Bhatnagar D. // Appl. Microbiol. Biotechnol. 2006, V.71, №5, P.575-586</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>[7] Jäger A., Levy M.J., Hecht S.M. // Biochemistry. 1988, V.27, №19, P.7237-7246</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>[8] Stetsenko D.A., Kupryushkin M.S., Pyshnyi D.V. // WO patent application PCT /RU 2014/000647, priority from 22.08.2014. 2014</mixed-citation></ref></ref-list></back></article>
